Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 675

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 675
---
,927,438 |

____________ (*)Rest of the world (“ROW”) represents 7 major countries except China. These markets were separated purely from a licensing perspective, as the pre -determinedterms would be applied when licensing out its technologies due to the license agreement with China Medical System Corp. (1) VXM01 VXM01 is an oral T -cellimmunotherapy that is designed to activate T -cellsto attack the tumor vasculature and tumor cells. VXM01 carries the vascular endothelial growth factor receptor -2(VEGFR2), which is highly overexpressed on the tumor vasculature. The active, T -cell-mediateddestruction of tumor vasculature cells leads to an increased infiltration of various immune cells into tumor tissue.

| Project code |     | Supplementary explanation of project                                                                                                                                                                                                                                                                                                                                                                                                                           |
| VXM01-GBM    |     | GBM is a cancer with some of the highest unmet needs. It is one of the most common and most lethal primary brain tumors. The current standard of care consists of surgery followed by radiation and temozolomide. However, there is no standard therapy which prove extension of survival rate. Therefore, it is expected that VXM01 can be applied to GBM and prove its efficacy in treating GBM.                                                             |
| VXM01-mCRC   |     | Colorectal cancer is the third most commonly occurring cancer worldwide and the second most deadly cancer. In early stage, CRC is commonly treated with surgery, while metastatic CRC treatment is dominated by fluorouracil chemotherapy regimens in combination with angiogenesis inhibitors. However, patients still become refractory to these drugs. Therefore, it is expected that VXM01 can be applied to mCRC and prove its efficacy in treating mCRC. |
| VXM01-Liver  |     | Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and accounts for 75 – 90% of all primary liver cancers, making it the third leading cause of cancer mortality worldwide. The current approved therapy has shown a low response rate for the limited number of patients. Therefore, it is expected that VXM01 can be applied to liver cancer and prove its efficacy in treating liver cancer.                                    |
| VXM01-NF2    |     | Neurofibromatosis (NF) is a tumor originating in the nervous system. In neurofibromatosis type 2, the most common tumors are vestibular schwannomas or acoustic